Screener
Wave Life Sciences WVE SG — Deferred Income Tax Expense Benefit
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxExpenseBenefit.
The source filing: Wave Life Sciences’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 7:50 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-073472
| Current benefit for income taxes: / Singapore | Year Ended December 31, 2025 / $ | Year Ended December 31, 2025 / — | Year Ended December 31, 2024 / $ | Year Ended December 31, 2024 / — | Year Ended December 31, 2023 / — |
|---|---|---|---|---|---|
| Rest of world | — | — | 677 | ||
| Total current benefit for income taxes | $ | — | $ | — | $677 |
| Deferred benefit for income taxes: | |||||
| Singapore | $ | — | $ | — | $— |
| Rest of world | — | — | — | ||
| Total deferred benefit for income taxes | $ | — | $ | — | $— |
| Total benefit for income taxes | $ | — | $ | — | $677 |
Item 16. Form 10-K Summary
FAQ
- What is Wave Life Sciences's SG — deferred income tax expense benefit?
- Wave Life Sciences (WVE) reported SG — deferred income tax expense benefit of $0 in Q4 2025.
- What does SG — deferred income tax expense benefit mean?
- Captures the tax effects of temporary differences between the financial reporting and tax bases of assets and liabilities within the segment. This metric indicates future tax obligations or benefits that will materialize as these differences reverse.
Ask your AI about Wave Life Sciences's sg — deferred income tax expense benefit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude